{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:24:34Z","timestamp":1788456274930,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,7]]},"DOI":"10.7759\/cureus.48442","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T14:44:51Z","timestamp":1699368291000},"source":"Crossref","is-referenced-by-count":6,"title":["The Role of Serological Markers in the Prediction of Disease Course and Response to Therapy in Inflammatory Bowel Disease"],"prefix":"10.7759","author":[{"given":"Maiss","family":"Reghefaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariladei S","family":"Peresuodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michell S","family":"Saavedra Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chijioke","family":"Orji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiba","family":"Reghefaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v4.i5.446","article-title":"Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies","volume":"4","author":"Xia B","year":"1998","unstructured":"Xia B, Crusius J, Meuwissen S, Pe?a A. Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies. World J Gastroenterol. 1998, 4:446-58. 10.3748\/wjg.v4.i5.446","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v6.i1.13","article-title":"Laboratory markers in ulcerative colitis: current insights and future advances","volume":"6","author":"Cioffi M","year":"2015","unstructured":"Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT. Laboratory markers in ulcerative colitis: current insights and future advances. World J Gastrointest Pathophysiol. 2015, 6:13-22. 10.4291\/wjgp.v6.i1.13","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14872","article-title":"The epidemiology of inflammatory bowel disease: East meets West","volume":"35","author":"Mak WY","year":"2020","unstructured":"Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets West. J Gastroenterol Hepatol. 2020, 35:380-9. 10.1111\/jgh.14872","journal-title":"J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0953-6205(00)00090-x","article-title":"Changes in the incidence of inflammatory bowel disease: what does it mean?","volume":"11","author":"Russel MG","year":"2000","unstructured":"Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean?. Eur J Intern Med. 2000, 11:191-6. 10.1016\/s0953-6205(00)00090-x","journal-title":"Eur J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S57982","article-title":"Inflammatory bowel disease and anxiety: links, risks, and challenges faced","volume":"8","author":"Bannaga AS","year":"2015","unstructured":"Bannaga AS, Selinger CP. Inflammatory bowel disease and anxiety: links, risks, and challenges faced. Clin Exp Gastroenterol. 2015, 8:111-7. 10.2147\/CEG.S57982","journal-title":"Clin Exp Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8553(05)70057-1","article-title":"Current theories on the causes of inflammatory bowel disease","volume":"28","author":"Papadakis KA","year":"1999","unstructured":"Papadakis KA, Targan SR. Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am. 1999, 28:283-96. 10.1016\/s0889-8553(05)70057-1","journal-title":"Gastroenterol Clin North Am"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2017.393","article-title":"Novel treatments for inflammatory bowel disease","volume":"33","author":"Lee HS","year":"2018","unstructured":"Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med. 2018, 33:20-7. 10.3904\/kjim.2017.393","journal-title":"Korean J Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666090-00002","article-title":"Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin","volume":"66","author":"Lanzarotto F","year":"2006","unstructured":"Lanzarotto F, Carpani M, Chaudhary R, Ghosh S. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Drugs. 2006, 66:1179-89. 10.2165\/00003495-200666090-00002","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12413","article-title":"The emerging global epidemic of paediatric inflammatory bowel disease - causes and consequences","volume":"279","author":"Malmborg P","year":"2016","unstructured":"Malmborg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease - causes and consequences. J Intern Med. 2016, 279:241-58. 10.1111\/joim.12413","journal-title":"J Intern Med"},{"key":"ref10","article-title":"Environmental risk factors for inflammatory bowel disease","volume":"9","author":"Ananthakrishnan AN","year":"2013","unstructured":"Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013, 9:367-74.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000903","article-title":"New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes","volume":"22","author":"Barnes EL","year":"2016","unstructured":"Barnes EL, Burakoff R. New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes. Inflamm Bowel Dis. 2016, 22:2956-65. 10.1097\/MIB.0000000000000903","journal-title":"Inflamm Bowel Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22957","article-title":"Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease","volume":"18","author":"Christophi GP","year":"2012","unstructured":"Christophi GP, Rong R, Holtzapple PG, Massa PT, Landas SK. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2012, 18:2342-56. 10.1002\/ibd.22957","journal-title":"Inflamm Bowel Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.129473","article-title":"Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties","volume":"20","author":"Mosli M","year":"2014","unstructured":"Mosli M, Al Beshir M, Al-Judaibi B, et al.. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol. 2014, 20:81-101. 10.4103\/1319-3767.129473","journal-title":"Saudi J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2009.0123","article-title":"The diagnosis and treatment of Crohn's disease and ulcerative colitis","volume":"106","author":"Baumgart DC","year":"2009","unstructured":"Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int. 2009, 106:123-33. 10.3238\/arztebl.2009.0123","journal-title":"Dtsch Arztebl Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.04.010","article-title":"Crohn disease: epidemiology, diagnosis, and management","volume":"92","author":"Feuerstein JD","year":"2017","unstructured":"Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017, 92:1088-103. 10.1016\/j.mayocp.2017.04.010","journal-title":"Mayo Clin Proc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2007.06.005","article-title":"Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey","volume":"1","author":"Ghosh S","year":"2007","unstructured":"Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007, 1:10-20. 10.1016\/j.crohns.2007.06.005","journal-title":"J Crohns Colitis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: clinical aspects and treatments","volume":"7","author":"Fakhoury M","year":"2014","unstructured":"Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014, 7:113-20. 10.2147\/JIR.S65979","journal-title":"J Inflamm Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.09.001","article-title":"Diagnostics of inflammatory bowel disease","volume":"133","author":"Nikolaus S","year":"2007","unstructured":"Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007, 133:1670-89. 10.1053\/j.gastro.2007.09.001","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-014-0416-y","article-title":"The use of prognostic factors in inflammatory bowel diseases","volume":"16","author":"Billiet T","year":"2014","unstructured":"Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014, 16:416. 10.1007\/s11894-014-0416-y","journal-title":"Curr Gastroenterol Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-199902000-00009","article-title":"Lack of current clinical value of serological testing in the evaluation of patients with IBD","volume":"5","author":"MacDermott RP","year":"1999","unstructured":"MacDermott RP. Lack of current clinical value of serological testing in the evaluation of patients with IBD. Inflamm Bowel Dis. 1999, 5:64-5. 10.1097\/00054725-199902000-00009","journal-title":"Inflamm Bowel Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.058560","article-title":"Serologic markers in inflammatory bowel disease","volume":"52","author":"Bossuyt X","year":"2006","unstructured":"Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006, 52:171-81. 10.1373\/clinchem.2005.058560","journal-title":"Clin Chem"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1111\/j.1572-0241.2002.05689.x","article-title":"Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn\u2019s disease","volume":"97","author":"Esters N","year":"2002","unstructured":"Esters N, Vermeire S, Joossens S, et al.. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn\u2019s disease. Am J Gastroenterol. 2002, 97:1458-62.","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4065\/71.5.431","article-title":"Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study","volume":"71","author":"Sandborn WJ","year":"1996","unstructured":"Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996, 71:431-6. 10.4065\/71.5.431","journal-title":"Mayo Clin Proc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0333-z","article-title":"C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study","volume":"15","author":"Iwasa R","year":"2015","unstructured":"Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol. 2015, 15:103. 10.1186\/s12876-015-0333-z","journal-title":"BMC Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/01.ibd.0000227626.72271.91","article-title":"Fecal S100A12: a novel noninvasive marker in children with Crohn's disease","volume":"12","author":"de Jong NS","year":"2006","unstructured":"de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis. 2006, 12:566-72. 10.1097\/01.ibd.0000227626.72271.91","journal-title":"Inflamm Bowel Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3369","article-title":"Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis","volume":"341","author":"van Rheenen PF","year":"2010","unstructured":"van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010, 341:c3369. 10.1136\/bmj.c3369","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/00365520701427094","article-title":"Relationship between fecal lactoferrin and inflammatory bowel disease","volume":"42","author":"Dai J","year":"2007","unstructured":"Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007, 42:1440-4. 10.1080\/00365520701427094","journal-title":"Scand J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20933","article-title":"Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse","volume":"15","author":"Gisbert JP","year":"2009","unstructured":"Gisbert JP, Bermejo F, P\u00e9rez-Calle JL, et al.. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009, 15:1190-8. 10.1002\/ibd.20933","journal-title":"Inflamm Bowel Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22863","article-title":"Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF\u03b1 blocking agents","volume":"18","author":"Molander P","year":"2012","unstructured":"Molander P, af Bj\u00f6rkesten CG, Mustonen H, et al.. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF\u03b1 blocking agents. Inflamm Bowel Dis. 2012, 18:2011-7. 10.1002\/ibd.22863","journal-title":"Inflamm Bowel Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000515","article-title":"Lipocalin-2 is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-\u03b1 and modulated by IL23R genotype status","volume":"21","author":"Stallhofer J","year":"2015","unstructured":"Stallhofer J, Friedrich M, Konrad-Zerna A, et al.. Lipocalin-2 is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-\u03b1 and modulated by IL23R genotype status. Inflamm Bowel Dis. 2015, 21:2327-40. 10.1097\/MIB.0000000000000515","journal-title":"Inflamm Bowel Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0086-4","article-title":"NOX1-derived ROS drive the expression of Lipocalin-2 in colonic epithelial cells in inflammatory conditions","volume":"12","author":"Makhezer N","year":"2019","unstructured":"Makhezer N, Ben Khemis M, Liu D, et al.. NOX1-derived ROS drive the expression of Lipocalin-2 in colonic epithelial cells in inflammatory conditions. Mucosal Immunol. 2019, 12:117-31. 10.1038\/s41385-018-0086-4","journal-title":"Mucosal Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-011-0516-5","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity","volume":"47","author":"Oikonomou KA","year":"2012","unstructured":"Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012, 47:519-30. 10.1007\/s00535-011-0516-5","journal-title":"J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.10.5.856-861.2003","article-title":"Distinct elevation of levels of anti-Caenorhabditis elegans antibody in sera of patients with inflammatory bowel disease","volume":"10","author":"Oshitani N","year":"2003","unstructured":"Oshitani N, Hato F, Kitagawa S, et al.. Distinct elevation of levels of anti-Caenorhabditis elegans antibody in sera of patients with inflammatory bowel disease. Clin Diagn Lab Immunol. 2003, 10:856-61. 10.1128\/cdli.10.5.856-861.2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-005-0013-0","article-title":"Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation","volume":"48","author":"Hui T","year":"2005","unstructured":"Hui T, Landers C, Vasiliauskas E, et al.. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005, 48:1254-62. 10.1007\/s10350-005-0013-0","journal-title":"Dis Colon Rectum"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i3.1304","article-title":"Antibody markers in the diagnosis of inflammatory bowel disease","volume":"22","author":"Mitsuyama K","year":"2016","unstructured":"Mitsuyama K, Niwa M, Takedatsu H, et al.. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016, 22:1304-10. 10.3748\/wjg.v22.i3.1304","journal-title":"World J Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.108043","article-title":"New serological markers in inflammatory bowel disease are associated with complicated disease behaviour","volume":"56","author":"Ferrante M","year":"2007","unstructured":"Ferrante M, Henckaerts L, Joossens M, et al.. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007, 56:1394-403. 10.1136\/gut.2006.108043","journal-title":"Gut"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.12.6567-6575.2002","article-title":"Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen","volume":"70","author":"Wei B","year":"2002","unstructured":"Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immun. 2002, 70:6567-75. 10.1128\/IAI.70.12.6567-6575.2002","journal-title":"Infect Immun"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.04.030","article-title":"Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease","volume":"131","author":"Dotan I","year":"2006","unstructured":"Dotan I, Fishman S, Dgani Y, et al.. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006, 131:366-78. 10.1053\/j.gastro.2006.04.030","journal-title":"Gastroenterology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.79","article-title":"Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype","volume":"104","author":"Seow CH","year":"2009","unstructured":"Seow CH, Stempak JM, Xu W, et al.. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009, 104:1426-34. 10.1038\/ajg.2009.79","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/183386-the-role-of-serological-markers-in-the-prediction-of-disease-course-and-response-to-therapy-in-inflammatory-bowel-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:21Z","timestamp":1707509361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/183386-the-role-of-serological-markers-in-the-prediction-of-disease-course-and-response-to-therapy-in-inflammatory-bowel-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.48442","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,7]]}}}